Post-Progression Analysis of EGFR -Mutant NSCLC Following Osimertinib Therapy in Real-World Settings.
Ilaria AttiliCarla CorvajaGianluca SpitaleriPamela Trillo AliagaEster Del SignoreAntonio PassaroFilippo de MarinisPublished in: Cancers (2024)
-mutant NSCLC patients. Clinical and CNS-specific outcomes in patients receiving standard chemotherapy after the failure of osimertinib are dismal. Novel upfront treatment options with demonstrated prolonged PFS and better CNS outcomes may help address this important issue.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- newly diagnosed
- ejection fraction
- brain metastases
- blood brain barrier
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- tyrosine kinase
- wild type
- locally advanced
- mesenchymal stem cells
- bone marrow